| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acupuncture Therapy | 30 | 2023 | 38 | 17.380 |
Why?
|
| Neoplasms | 46 | 2023 | 1058 | 13.830 |
Why?
|
| Cancer Survivors | 22 | 2022 | 75 | 11.750 |
Why?
|
| Integrative Medicine | 10 | 2022 | 35 | 6.370 |
Why?
|
| Integrative Oncology | 8 | 2023 | 8 | 6.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 8 | 2023 | 44 | 5.640 |
Why?
|
| Breast Neoplasms | 23 | 2021 | 1036 | 5.520 |
Why?
|
| Aromatase Inhibitors | 10 | 2019 | 34 | 4.970 |
Why?
|
| Cancer Pain | 7 | 2023 | 17 | 4.240 |
Why?
|
| Arthralgia | 7 | 2019 | 38 | 3.770 |
Why?
|
| Medical Oncology | 11 | 2023 | 40 | 3.760 |
Why?
|
| Pain Management | 10 | 2022 | 121 | 3.750 |
Why?
|
| Chronic Pain | 5 | 2021 | 108 | 3.180 |
Why?
|
| Electroacupuncture | 5 | 2021 | 8 | 3.160 |
Why?
|
| Music Therapy | 4 | 2021 | 20 | 3.130 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2021 | 29 | 3.110 |
Why?
|
| Transcription Factors | 23 | 2022 | 1356 | 3.000 |
Why?
|
| Musculoskeletal Pain | 4 | 2021 | 23 | 2.970 |
Why?
|
| Drugs, Chinese Herbal | 4 | 2023 | 12 | 2.940 |
Why?
|
| Yoga | 5 | 2022 | 18 | 2.830 |
Why?
|
| Hedgehog Proteins | 15 | 2017 | 110 | 2.780 |
Why?
|
| Pain | 6 | 2022 | 309 | 2.650 |
Why?
|
| Plants, Medicinal | 4 | 2023 | 55 | 2.640 |
Why?
|
| Humans | 114 | 2023 | 49675 | 2.630 |
Why?
|
| Fatigue | 7 | 2020 | 101 | 2.530 |
Why?
|
| Low Back Pain | 3 | 2021 | 109 | 2.140 |
Why?
|
| Complementary Therapies | 7 | 2021 | 60 | 2.120 |
Why?
|
| Cross-Sectional Studies | 22 | 2022 | 2125 | 2.110 |
Why?
|
| Middle Aged | 41 | 2021 | 13451 | 2.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 14 | 2022 | 366 | 2.010 |
Why?
|
| Female | 63 | 2022 | 26343 | 2.000 |
Why?
|
| Sleep Wake Disorders | 3 | 2023 | 64 | 1.970 |
Why?
|
| Radiation Oncology | 2 | 2023 | 40 | 1.830 |
Why?
|
| Mind-Body Therapies | 4 | 2021 | 10 | 1.790 |
Why?
|
| Analgesics | 4 | 2022 | 89 | 1.790 |
Why?
|
| Aged | 29 | 2022 | 10870 | 1.650 |
Why?
|
| Adult | 31 | 2022 | 13334 | 1.590 |
Why?
|
| Massage | 3 | 2021 | 12 | 1.580 |
Why?
|
| Trans-Activators | 12 | 2022 | 281 | 1.570 |
Why?
|
| Acupuncture | 2 | 2020 | 4 | 1.560 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 533 | 1.550 |
Why?
|
| Treatment Outcome | 16 | 2021 | 3888 | 1.430 |
Why?
|
| Insurance Coverage | 2 | 2019 | 96 | 1.430 |
Why?
|
| Anxiety | 5 | 2020 | 310 | 1.420 |
Why?
|
| Male | 39 | 2022 | 23140 | 1.360 |
Why?
|
| Mesoderm | 6 | 2017 | 79 | 1.360 |
Why?
|
| Anti-Anxiety Agents | 3 | 2018 | 30 | 1.300 |
Why?
|
| DNA-Binding Proteins | 11 | 2016 | 1042 | 1.230 |
Why?
|
| Cell Cycle Proteins | 6 | 2020 | 358 | 1.220 |
Why?
|
| Phosphoproteins | 10 | 2020 | 202 | 1.220 |
Why?
|
| Surveys and Questionnaires | 10 | 2022 | 2287 | 1.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 264 | 1.200 |
Why?
|
| Signal Transduction | 32 | 2022 | 2689 | 1.190 |
Why?
|
| Quality of Life | 14 | 2022 | 736 | 1.190 |
Why?
|
| Accidental Falls | 2 | 2018 | 130 | 1.180 |
Why?
|
| Nuclear Proteins | 8 | 2018 | 750 | 1.140 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2014 | 46 | 1.120 |
Why?
|
| Exercise | 5 | 2021 | 795 | 1.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 66 | 1.020 |
Why?
|
| Gastrointestinal Tract | 3 | 2017 | 155 | 1.010 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 110 | 0.990 |
Why?
|
| Hospitals, Community | 2 | 2021 | 62 | 0.940 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 210 | 0.940 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2022 | 1 | 0.940 |
Why?
|
| Web Browser | 2 | 2019 | 9 | 0.930 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 104 | 0.920 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2023 | 7 | 0.880 |
Why?
|
| Acupuncture, Ear | 1 | 2021 | 1 | 0.860 |
Why?
|
| Medicine, Traditional | 1 | 2021 | 7 | 0.850 |
Why?
|
| Postmenopause | 3 | 2019 | 294 | 0.850 |
Why?
|
| Plant Preparations | 1 | 2021 | 17 | 0.850 |
Why?
|
| Mice | 35 | 2022 | 9096 | 0.850 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 277 | 0.840 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 34 | 0.840 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 356 | 0.830 |
Why?
|
| Constipation | 1 | 2021 | 18 | 0.830 |
Why?
|
| Depression | 5 | 2021 | 748 | 0.820 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4220 | 0.810 |
Why?
|
| Intestines | 3 | 2020 | 141 | 0.780 |
Why?
|
| Hot Flashes | 2 | 2020 | 88 | 0.780 |
Why?
|
| Uveal Neoplasms | 1 | 2019 | 51 | 0.770 |
Why?
|
| Melanoma | 2 | 2020 | 281 | 0.770 |
Why?
|
| Animals | 47 | 2022 | 17732 | 0.760 |
Why?
|
| Caregivers | 2 | 2020 | 157 | 0.760 |
Why?
|
| Music | 1 | 2020 | 71 | 0.760 |
Why?
|
| Cell Differentiation | 8 | 2017 | 1233 | 0.750 |
Why?
|
| Dance Therapy | 1 | 2019 | 1 | 0.740 |
Why?
|
| Carcinogenesis | 2 | 2018 | 112 | 0.730 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 437 | 0.730 |
Why?
|
| Aromatase | 1 | 2018 | 16 | 0.720 |
Why?
|
| Biomedical Enhancement | 1 | 2018 | 1 | 0.720 |
Why?
|
| Sleep | 5 | 2023 | 199 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 596 | 0.720 |
Why?
|
| Wnt Proteins | 11 | 2013 | 89 | 0.720 |
Why?
|
| Medicare | 2 | 2020 | 458 | 0.710 |
Why?
|
| Transcription, Genetic | 6 | 2016 | 821 | 0.710 |
Why?
|
| Plant Extracts | 2 | 2018 | 148 | 0.700 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2013 | 108 | 0.700 |
Why?
|
| Phytotherapy | 3 | 2022 | 54 | 0.690 |
Why?
|
| Nerve Tissue Proteins | 6 | 2016 | 390 | 0.690 |
Why?
|
| Stem Cells | 5 | 2020 | 239 | 0.680 |
Why?
|
| Family Relations | 1 | 2018 | 22 | 0.680 |
Why?
|
| Survivors | 2 | 2020 | 139 | 0.680 |
Why?
|
| Needs Assessment | 2 | 2017 | 159 | 0.670 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 258 | 0.660 |
Why?
|
| United States | 10 | 2023 | 6234 | 0.660 |
Why?
|
| Epithelium | 1 | 2017 | 97 | 0.650 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 95 | 0.650 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2017 | 10 | 0.650 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 84 | 0.650 |
Why?
|
| Zinc Finger Protein GLI1 | 6 | 2022 | 32 | 0.640 |
Why?
|
| Amines | 1 | 2017 | 29 | 0.640 |
Why?
|
| Matricaria | 1 | 2016 | 1 | 0.630 |
Why?
|
| Young Adult | 8 | 2019 | 3701 | 0.630 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 49 | 0.620 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 256 | 0.620 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 49 | 0.620 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2017 | 67 | 0.620 |
Why?
|
| Taxoids | 1 | 2016 | 26 | 0.610 |
Why?
|
| Telemedicine | 1 | 2020 | 235 | 0.610 |
Why?
|
| Mice, Transgenic | 12 | 2021 | 1114 | 0.600 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 284 | 0.600 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 37 | 0.590 |
Why?
|
| Rhabdomyosarcoma | 2 | 2013 | 14 | 0.590 |
Why?
|
| Anxiety Disorders | 2 | 2018 | 154 | 0.580 |
Why?
|
| beta Catenin | 4 | 2013 | 84 | 0.580 |
Why?
|
| Biomedical Research | 4 | 2020 | 237 | 0.570 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 300 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 714 | 0.560 |
Why?
|
| Muscle Proteins | 1 | 2016 | 105 | 0.560 |
Why?
|
| Cell Proliferation | 8 | 2020 | 884 | 0.550 |
Why?
|
| Placebo Effect | 1 | 2014 | 9 | 0.550 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2021 | 33 | 0.550 |
Why?
|
| Cell Lineage | 3 | 2013 | 237 | 0.550 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 300 | 0.550 |
Why?
|
| Zebrafish Proteins | 8 | 2004 | 144 | 0.550 |
Why?
|
| Repressor Proteins | 5 | 2021 | 309 | 0.520 |
Why?
|
| GTP-Binding Proteins | 3 | 1998 | 77 | 0.520 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2012 | 281 | 0.520 |
Why?
|
| Program Evaluation | 1 | 2017 | 463 | 0.520 |
Why?
|
| Cell Movement | 1 | 2016 | 386 | 0.510 |
Why?
|
| Proteins | 9 | 2005 | 707 | 0.510 |
Why?
|
| Self Report | 3 | 2021 | 324 | 0.500 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2013 | 11 | 0.500 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2013 | 10 | 0.490 |
Why?
|
| Body Patterning | 2 | 2014 | 76 | 0.490 |
Why?
|
| Cognition | 3 | 2022 | 381 | 0.480 |
Why?
|
| Pain Measurement | 3 | 2020 | 248 | 0.470 |
Why?
|
| Pilot Projects | 5 | 2022 | 753 | 0.460 |
Why?
|
| Genes, ras | 1 | 2012 | 29 | 0.450 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2002 | 110 | 0.450 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2022 | 80 | 0.450 |
Why?
|
| Logistic Models | 4 | 2019 | 1159 | 0.450 |
Why?
|
| Retrospective Studies | 5 | 2023 | 4517 | 0.440 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2021 | 7 | 0.430 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 1249 | 0.430 |
Why?
|
| Mammals | 2 | 2010 | 155 | 0.410 |
Why?
|
| Herbal Medicine | 2 | 2023 | 5 | 0.410 |
Why?
|
| Zinc Finger Protein Gli3 | 3 | 2016 | 8 | 0.410 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 32 | 0.410 |
Why?
|
| Zinc Finger Protein Gli2 | 3 | 2016 | 25 | 0.410 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 186 | 0.400 |
Why?
|
| Drosophila melanogaster | 4 | 2021 | 471 | 0.400 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 237 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 501 | 0.400 |
Why?
|
| Feasibility Studies | 3 | 2020 | 429 | 0.400 |
Why?
|
| Meditation | 2 | 2021 | 54 | 0.390 |
Why?
|
| Receptors, LDL | 4 | 2004 | 32 | 0.390 |
Why?
|
| Patient-Centered Care | 3 | 2019 | 225 | 0.390 |
Why?
|
| Intestinal Mucosa | 4 | 2019 | 193 | 0.390 |
Why?
|
| Smoothened Receptor | 6 | 2013 | 24 | 0.380 |
Why?
|
| Age Factors | 3 | 2018 | 1410 | 0.380 |
Why?
|
| Patient Participation | 2 | 2022 | 185 | 0.380 |
Why?
|
| Fibroblast Growth Factor 8 | 1 | 2009 | 5 | 0.370 |
Why?
|
| Receptors, Cell Surface | 4 | 2014 | 401 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2009 | 19 | 0.370 |
Why?
|
| Embryo, Mammalian | 2 | 2010 | 151 | 0.360 |
Why?
|
| Gene Expression Regulation | 4 | 2005 | 1498 | 0.360 |
Why?
|
| Extremities | 1 | 2009 | 55 | 0.360 |
Why?
|
| Risk Factors | 4 | 2019 | 4248 | 0.360 |
Why?
|
| Vertebrates | 1 | 2009 | 39 | 0.360 |
Why?
|
| Mobile Applications | 2 | 2021 | 95 | 0.350 |
Why?
|
| Qualitative Research | 2 | 2021 | 432 | 0.350 |
Why?
|
| 3T3 Cells | 10 | 2002 | 99 | 0.350 |
Why?
|
| Prospective Studies | 4 | 2018 | 2520 | 0.340 |
Why?
|
| Dietary Supplements | 2 | 2021 | 209 | 0.330 |
Why?
|
| Neoplasms, Experimental | 2 | 2009 | 65 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 459 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 423 | 0.320 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 2013 | 29 | 0.320 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2021 | 587 | 0.320 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 755 | 0.310 |
Why?
|
| Cells, Cultured | 4 | 2013 | 2017 | 0.310 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 1787 | 0.310 |
Why?
|
| Protein Binding | 5 | 2020 | 1475 | 0.300 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1936 | 0.300 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 360 | 0.300 |
Why?
|
| Double-Blind Method | 3 | 2020 | 549 | 0.300 |
Why?
|
| Disease Progression | 2 | 2019 | 718 | 0.300 |
Why?
|
| Immunoblotting | 2 | 2017 | 180 | 0.280 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 189 | 0.280 |
Why?
|
| Drosophila Proteins | 3 | 2018 | 664 | 0.270 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2002 | 58 | 0.260 |
Why?
|
| Integrin alpha6beta1 | 2 | 2015 | 33 | 0.260 |
Why?
|
| Molecular Sequence Data | 7 | 2016 | 1886 | 0.250 |
Why?
|
| Prevalence | 2 | 2018 | 1121 | 0.250 |
Why?
|
| Time Factors | 5 | 2017 | 3127 | 0.250 |
Why?
|
| Integrases | 3 | 2009 | 30 | 0.240 |
Why?
|
| Seeds | 1 | 2023 | 31 | 0.240 |
Why?
|
| Child | 3 | 2022 | 3791 | 0.230 |
Why?
|
| Interleukin-33 | 1 | 2022 | 14 | 0.230 |
Why?
|
| Medical Marijuana | 1 | 2022 | 11 | 0.230 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 41 | 0.230 |
Why?
|
| Medicine, East Asian Traditional | 1 | 2022 | 4 | 0.230 |
Why?
|
| Cannabinoids | 1 | 2022 | 25 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 75 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 157 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 499 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2022 | 75 | 0.220 |
Why?
|
| Cannabis | 1 | 2022 | 29 | 0.220 |
Why?
|
| Gene Deletion | 2 | 2021 | 297 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 106 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2019 | 175 | 0.220 |
Why?
|
| Tibet | 1 | 2021 | 3 | 0.220 |
Why?
|
| Diclofenac | 1 | 2021 | 3 | 0.220 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 12 | 0.210 |
Why?
|
| Cohort Studies | 3 | 2018 | 2064 | 0.210 |
Why?
|
| Genomic Instability | 1 | 2021 | 53 | 0.210 |
Why?
|
| Cell Nucleus | 2 | 2018 | 558 | 0.210 |
Why?
|
| Defecation | 1 | 2021 | 12 | 0.210 |
Why?
|
| Adolescent | 4 | 2020 | 5324 | 0.210 |
Why?
|
| COS Cells | 5 | 2002 | 168 | 0.210 |
Why?
|
| Tai Ji | 1 | 2020 | 5 | 0.210 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 77 | 0.210 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 129 | 0.200 |
Why?
|
| Confidence Intervals | 2 | 2019 | 256 | 0.200 |
Why?
|
| DNA Transposable Elements | 1 | 2021 | 123 | 0.200 |
Why?
|
| Erdheim-Chester Disease | 1 | 2020 | 1 | 0.200 |
Why?
|
| Pennsylvania | 1 | 2020 | 57 | 0.200 |
Why?
|
| Ligustrum | 1 | 2020 | 1 | 0.200 |
Why?
|
| Reishi | 1 | 2020 | 2 | 0.200 |
Why?
|
| Estradiol Dehydrogenases | 1 | 2019 | 1 | 0.190 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 95 | 0.190 |
Why?
|
| Psychotherapy | 1 | 2020 | 89 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 179 | 0.190 |
Why?
|
| Phosphorylation | 6 | 2019 | 790 | 0.190 |
Why?
|
| Endothelial Cells | 1 | 2021 | 160 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2019 | 114 | 0.190 |
Why?
|
| SOXC Transcription Factors | 2 | 2022 | 8 | 0.190 |
Why?
|
| Morphine | 1 | 2019 | 48 | 0.190 |
Why?
|
| Motivation | 1 | 2021 | 240 | 0.190 |
Why?
|
| Oxycodone | 1 | 2019 | 31 | 0.190 |
Why?
|
| Kidney | 1 | 2021 | 344 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 77 | 0.180 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 349 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 187 | 0.180 |
Why?
|
| Melanocytes | 1 | 2019 | 65 | 0.180 |
Why?
|
| Affect | 1 | 2019 | 110 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 128 | 0.180 |
Why?
|
| Mice, 129 Strain | 2 | 2020 | 36 | 0.180 |
Why?
|
| Quality Improvement | 1 | 2023 | 321 | 0.180 |
Why?
|
| Outpatients | 1 | 2019 | 114 | 0.180 |
Why?
|
| Contusions | 1 | 2018 | 10 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 175 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2019 | 301 | 0.170 |
Why?
|
| Prognosis | 2 | 2020 | 1251 | 0.170 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2018 | 1 | 0.170 |
Why?
|
| Educational Status | 1 | 2019 | 258 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 422 | 0.170 |
Why?
|
| Mindfulness | 1 | 2019 | 49 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 451 | 0.170 |
Why?
|
| Androstadienes | 2 | 2016 | 14 | 0.170 |
Why?
|
| Paclitaxel | 1 | 2018 | 62 | 0.170 |
Why?
|
| Smartphone | 1 | 2018 | 45 | 0.170 |
Why?
|
| Yeasts | 1 | 2018 | 51 | 0.170 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2018 | 31 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 165 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 56 | 0.170 |
Why?
|
| Medulloblastoma | 2 | 2008 | 9 | 0.170 |
Why?
|
| Inpatients | 1 | 2020 | 258 | 0.170 |
Why?
|
| Nitriles | 2 | 2016 | 56 | 0.170 |
Why?
|
| Triazoles | 2 | 2016 | 62 | 0.170 |
Why?
|
| Acyltransferases | 1 | 2017 | 23 | 0.170 |
Why?
|
| Comprehensive Health Care | 1 | 2017 | 20 | 0.170 |
Why?
|
| Culture | 1 | 2018 | 75 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 341 | 0.160 |
Why?
|
| HEK293 Cells | 1 | 2019 | 527 | 0.160 |
Why?
|
| Alleles | 3 | 2015 | 410 | 0.160 |
Why?
|
| Patient Preference | 1 | 2018 | 66 | 0.160 |
Why?
|
| Counseling | 1 | 2020 | 389 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1143 | 0.160 |
Why?
|
| Social Media | 1 | 2019 | 102 | 0.160 |
Why?
|
| Survivorship | 1 | 2017 | 6 | 0.160 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2016 | 1 | 0.160 |
Why?
|
| Infant, Newborn | 2 | 2019 | 1162 | 0.160 |
Why?
|
| Menopause, Premature | 1 | 2017 | 23 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 140 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 372 | 0.160 |
Why?
|
| Diet | 2 | 2019 | 603 | 0.160 |
Why?
|
| Heterografts | 1 | 2017 | 56 | 0.160 |
Why?
|
| Perception | 1 | 2018 | 162 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 33 | 0.150 |
Why?
|
| Transfection | 6 | 2016 | 614 | 0.150 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 18 | 0.150 |
Why?
|
| Cell Membrane | 2 | 2018 | 464 | 0.150 |
Why?
|
| Infant | 2 | 2019 | 1389 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 27 | 0.150 |
Why?
|
| Self Care | 1 | 2018 | 213 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2013 | 154 | 0.150 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2016 | 112 | 0.150 |
Why?
|
| Cell Self Renewal | 1 | 2016 | 11 | 0.150 |
Why?
|
| Disease Management | 1 | 2017 | 178 | 0.150 |
Why?
|
| Mutation | 4 | 2019 | 2190 | 0.150 |
Why?
|
| Breast | 1 | 2018 | 165 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2019 | 1707 | 0.150 |
Why?
|
| RNA Interference | 3 | 2016 | 580 | 0.150 |
Why?
|
| Medicaid | 1 | 2019 | 286 | 0.150 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2015 | 1 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2016 | 20 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 42 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 33 | 0.140 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 95 | 0.140 |
Why?
|
| Amino Acid Sequence | 6 | 2013 | 1500 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 199 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 591 | 0.140 |
Why?
|
| Recurrence | 1 | 2016 | 496 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2016 | 236 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 101 | 0.140 |
Why?
|
| Receptors, Notch | 2 | 2016 | 101 | 0.140 |
Why?
|
| Macrophages | 1 | 2020 | 914 | 0.140 |
Why?
|
| Serum Response Factor | 3 | 1998 | 5 | 0.140 |
Why?
|
| Placebos | 1 | 2014 | 73 | 0.140 |
Why?
|
| Laminin | 1 | 2015 | 74 | 0.130 |
Why?
|
| Menopause | 1 | 2017 | 233 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 811 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1042 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 415 | 0.130 |
Why?
|
| Regeneration | 1 | 2014 | 87 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2016 | 476 | 0.130 |
Why?
|
| PAX7 Transcription Factor | 1 | 2013 | 9 | 0.130 |
Why?
|
| Acupuncture Points | 1 | 2013 | 4 | 0.130 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2013 | 13 | 0.130 |
Why?
|
| Rhabdomyoma | 1 | 2013 | 1 | 0.130 |
Why?
|
| Genome, Human | 1 | 2016 | 214 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 6 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 130 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2014 | 129 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2013 | 43 | 0.130 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 24 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2013 | 1873 | 0.120 |
Why?
|
| Edar Receptor | 1 | 2013 | 1 | 0.120 |
Why?
|
| Exocrine Glands | 1 | 2013 | 2 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 99 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 113 | 0.120 |
Why?
|
| Aging | 1 | 2019 | 680 | 0.120 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 159 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2016 | 1388 | 0.120 |
Why?
|
| Base Sequence | 1 | 2016 | 1253 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 205 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 414 | 0.120 |
Why?
|
| Autocrine Communication | 1 | 2013 | 32 | 0.120 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 57 | 0.120 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 33 | 0.120 |
Why?
|
| Emotions | 1 | 2014 | 182 | 0.120 |
Why?
|
| Hair | 1 | 2013 | 72 | 0.110 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 30 | 0.110 |
Why?
|
| Models, Animal | 1 | 2013 | 197 | 0.110 |
Why?
|
| Biological Evolution | 1 | 2013 | 104 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 275 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2013 | 534 | 0.110 |
Why?
|
| Luciferases | 3 | 2002 | 95 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2016 | 34 | 0.110 |
Why?
|
| Neurons | 2 | 2008 | 757 | 0.110 |
Why?
|
| Protein Transport | 2 | 2003 | 376 | 0.110 |
Why?
|
| Smad Proteins | 1 | 2011 | 19 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 142 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 576 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2014 | 379 | 0.100 |
Why?
|
| Gastrula | 1 | 2010 | 12 | 0.100 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2002 | 25 | 0.100 |
Why?
|
| Paracrine Communication | 1 | 2010 | 15 | 0.100 |
Why?
|
| Models, Biological | 1 | 2016 | 1096 | 0.100 |
Why?
|
| Axin Protein | 4 | 2007 | 10 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 40 | 0.100 |
Why?
|
| Genes, Reporter | 4 | 2007 | 216 | 0.100 |
Why?
|
| Organogenesis | 1 | 2010 | 37 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2012 | 428 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 423 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 684 | 0.090 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 84 | 0.090 |
Why?
|
| Polydactyly | 1 | 2009 | 1 | 0.090 |
Why?
|
| Ectoderm | 1 | 2009 | 11 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 17 | 0.090 |
Why?
|
| Chick Embryo | 1 | 2009 | 51 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2009 | 113 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 173 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 222 | 0.090 |
Why?
|
| Cell Polarity | 1 | 2009 | 97 | 0.090 |
Why?
|
| Thrombin | 2 | 1998 | 47 | 0.090 |
Why?
|
| Psychometrics | 1 | 2010 | 347 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 452 | 0.090 |
Why?
|
| Self-Examination | 1 | 2008 | 2 | 0.090 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 430 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 25 | 0.090 |
Why?
|
| GTPase-Activating Proteins | 2 | 1998 | 61 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 2857 | 0.090 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 3 | 2004 | 4 | 0.080 |
Why?
|
| Phenotype | 3 | 2020 | 996 | 0.080 |
Why?
|
| LDL-Receptor Related Proteins | 3 | 2004 | 5 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 243 | 0.080 |
Why?
|
| Patched Receptors | 3 | 2014 | 11 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2008 | 73 | 0.080 |
Why?
|
| Sequence Alignment | 3 | 2013 | 279 | 0.080 |
Why?
|
| Gastric Mucosa | 1 | 2007 | 51 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 365 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2021 | 300 | 0.080 |
Why?
|
| Cell Line | 3 | 2011 | 1919 | 0.080 |
Why?
|
| Stomach | 1 | 2007 | 57 | 0.080 |
Why?
|
| Morphogenesis | 1 | 2007 | 108 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2003 | 661 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2001 | 36 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2021 | 28 | 0.070 |
Why?
|
| Spleen | 1 | 2007 | 450 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 143 | 0.070 |
Why?
|
| Xenopus Proteins | 2 | 2003 | 31 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 58 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 231 | 0.070 |
Why?
|
| Chimera | 1 | 2005 | 37 | 0.070 |
Why?
|
| Doxycycline | 1 | 2005 | 33 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 623 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 95 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2011 | 337 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2007 | 344 | 0.070 |
Why?
|
| Dishevelled Proteins | 5 | 2003 | 6 | 0.070 |
Why?
|
| Patched-1 Receptor | 2 | 2014 | 13 | 0.070 |
Why?
|
| Gene Expression | 2 | 2013 | 755 | 0.070 |
Why?
|
| Binding Sites | 3 | 2016 | 821 | 0.070 |
Why?
|
| Face | 1 | 2004 | 26 | 0.060 |
Why?
|
| Neural Crest | 1 | 2004 | 27 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 184 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 637 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 93 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2005 | 260 | 0.060 |
Why?
|
| Ovum | 1 | 2003 | 71 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 483 | 0.060 |
Why?
|
| Lipoylation | 1 | 2022 | 3 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 110 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2002 | 71 | 0.060 |
Why?
|
| Dronabinol | 1 | 2022 | 27 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2002 | 2 | 0.060 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2002 | 3 | 0.060 |
Why?
|
| Cicatrix | 1 | 2022 | 36 | 0.060 |
Why?
|
| Lac Operon | 1 | 2002 | 26 | 0.060 |
Why?
|
| Fibrosis | 1 | 2022 | 96 | 0.060 |
Why?
|
| Symptom Assessment | 1 | 2022 | 36 | 0.060 |
Why?
|
| Point Mutation | 1 | 2002 | 153 | 0.050 |
Why?
|
| Diarrhea | 1 | 2022 | 66 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 123 | 0.050 |
Why?
|
| Bone Density | 1 | 2002 | 159 | 0.050 |
Why?
|
| Cysteine | 1 | 2001 | 95 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2020 | 5 | 0.050 |
Why?
|
| Cadherins | 1 | 2021 | 66 | 0.050 |
Why?
|
| Arousal | 1 | 2021 | 49 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2001 | 125 | 0.050 |
Why?
|
| Medication Errors | 1 | 2021 | 109 | 0.050 |
Why?
|
| Heart | 1 | 2022 | 215 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2022 | 344 | 0.050 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 4 | 2000 | 10 | 0.050 |
Why?
|
| Health Behavior | 2 | 2017 | 465 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 177 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2019 | 43 | 0.050 |
Why?
|
| Genotype | 2 | 2017 | 590 | 0.050 |
Why?
|
| Myocardium | 1 | 2020 | 189 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 44 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 217 | 0.050 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 12 | 0.050 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1998 | 1 | 0.050 |
Why?
|
| Endothelins | 1 | 1998 | 2 | 0.050 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2018 | 3 | 0.050 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1998 | 9 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 1998 | 17 | 0.040 |
Why?
|
| Epidermis | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1998 | 119 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 30 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 59 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 430 | 0.040 |
Why?
|
| Arm | 1 | 2018 | 39 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 1998 | 293 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 656 | 0.040 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 256 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 91 | 0.040 |
Why?
|
| Premenopause | 1 | 2017 | 54 | 0.040 |
Why?
|
| Arsenicals | 1 | 2016 | 7 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2016 | 13 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2016 | 33 | 0.040 |
Why?
|
| Oxides | 1 | 2016 | 28 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 3 | 2007 | 175 | 0.040 |
Why?
|
| Digestion | 1 | 2018 | 120 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 378 | 0.040 |
Why?
|
| Kinetics | 1 | 1998 | 696 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2017 | 89 | 0.040 |
Why?
|
| Chromatin | 1 | 2021 | 541 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2016 | 5 | 0.040 |
Why?
|
| Receptor, Notch3 | 1 | 2016 | 9 | 0.040 |
Why?
|
| Leuprolide | 1 | 2016 | 17 | 0.040 |
Why?
|
| Protein Structure, Secondary | 2 | 2011 | 236 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 62 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 34 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 146 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 804 | 0.040 |
Why?
|
| Cilia | 1 | 2016 | 133 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 121 | 0.040 |
Why?
|
| Life Style | 1 | 2017 | 311 | 0.030 |
Why?
|
| Enzyme Activation | 3 | 2001 | 327 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 267 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 453 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 199 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 729 | 0.030 |
Why?
|
| Estradiol | 1 | 2016 | 253 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 528 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2016 | 191 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 484 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 275 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 837 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 981 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 621 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 47 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 380 | 0.030 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cell Division | 1 | 2014 | 398 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 143 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 28 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 852 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 178 | 0.030 |
Why?
|
| Scalp | 1 | 2013 | 25 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 115 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 498 | 0.030 |
Why?
|
| Xenopus | 2 | 2003 | 50 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2004 | 245 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2011 | 12 | 0.030 |
Why?
|
| Genes, Insect | 1 | 2011 | 88 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 54 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 277 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 147 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 286 | 0.020 |
Why?
|
| Glycogen Synthase Kinases | 2 | 1999 | 2 | 0.020 |
Why?
|
| Wnt1 Protein | 2 | 1999 | 10 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2009 | 27 | 0.020 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cerebrum | 1 | 2008 | 13 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2008 | 98 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 641 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 68 | 0.020 |
Why?
|
| WT1 Proteins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 110 | 0.020 |
Why?
|
| Transcription Factor 4 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2007 | 5 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cyclin D | 1 | 2007 | 5 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2007 | 6 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2007 | 32 | 0.020 |
Why?
|
| Endoderm | 1 | 2007 | 41 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 198 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 153 | 0.020 |
Why?
|
| Cyclins | 1 | 2007 | 36 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2007 | 74 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2008 | 118 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2004 | 755 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 91 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2008 | 184 | 0.020 |
Why?
|
| Students | 1 | 2008 | 197 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 755 | 0.020 |
Why?
|
| Skull | 1 | 2004 | 42 | 0.020 |
Why?
|
| Mandible | 1 | 2002 | 10 | 0.010 |
Why?
|
| Palate | 1 | 2002 | 8 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2002 | 13 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 54 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 159 | 0.010 |
Why?
|
| Pedigree | 1 | 2002 | 179 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 150 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 341 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 172 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2002 | 132 | 0.010 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2000 | 101 | 0.010 |
Why?
|
| Static Electricity | 1 | 2000 | 155 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 308 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 342 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 905 | 0.010 |
Why?
|
| Protein Folding | 1 | 2000 | 241 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1999 | 349 | 0.010 |
Why?
|
| Biomarkers | 1 | 2002 | 1002 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2000 | 1061 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1999 | 718 | 0.010 |
Why?
|